Jyothy Labs (532926) Q4 19/20 earnings summary

Executive summary

• FY20 consolidated revenue fell 5.6% to ₹1,711 crore; operating EBITDA was ₹251.1 crore and PAT ₹162.6 crore, with lost March sales from the COVID-19 lockdown a key factor.

• Gross margin improved to 47.4% from 46.5%; EBITDA margin eased to 14.7% from 15.5%.

• Essential and hygiene products, smaller affordable packs, alternate distribution, and digital initiatives were prioritized amid disruption and leadership transition.

Financial highlights

• Consolidated revenue from operations was ₹1,711.2 crore versus ₹1,813.6 crore in FY19, down 5.6%.

• Operating EBITDA was ₹251.1 crore versus ₹281.1 crore; margin was 14.7% versus 15.5%.

• Consolidated PAT was ₹162.6 crore versus ₹197.6 crore; EPS was ₹4.64 versus ₹5.62.

• Gross margin rose to 47.4% from 46.5%; advertisement and sales promotion expense increased 8.9% to ₹122.7 crore.

Outlook and guidance

• Essential and hygiene products were expected to support demand; plans included ramping production, expanding smaller SKUs and strengthening rural reach.

• FY21 industry revenue was forecast to decline 2–3% due to COVID-related supply and demand shocks; home care was expected to see strong traction.

• Management expected no material adverse impact in the medium to long term, while noting the pandemic’s actual impact remained uncertain and would be monitored.

• International expansion plans targeted Asian markets including the Middle East, Malaysia, Sri Lanka and Bangladesh.